Genvec Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/6/2017)
| Balance Sheet | Total Assets | 7,707,000.00 | ROE | – |
| Balance Sheet | Total Equity | 4,705,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -19,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -6,002,000.00 | – | – |
| Cashflow | Operating Cash Flow | -5,983,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -2.78 | Div. Yield | – |
| Income | Net Income | -5,787,000.00 | P/E | – |
| Income | Shares Outstanding | 2,000,000.00 | P/B | – |
| Income | Total Revenue | 511,000.00 | P/S | – |
Ratios calculated on: –
Company Description
GenVec, Inc. develops gene-based pharmaceuticals and therapies for the treatment of major medical needs. The Company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates that address needs in the areas of cardiovascular disease, cancer and other therapeutic areas.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.genvec.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more